4//SEC Filing
MAHAFFY PATRICK J 4
Accession 0000899243-21-009499
CIK 0001466301other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 6:39 PM ET
Size
12.6 KB
Accession
0000899243-21-009499
Insider Transaction Report
Form 4
MAHAFFY PATRICK J
DirectorPresident and CEO
Transactions
- Award
Stock Option (right to buy)
2021-03-01+80,000→ 80,000 totalExercise: $6.23Exp: 2031-03-01→ Common Stock (80,000 underlying) - Award
Stock Option (right to buy)
2021-03-01+40,000→ 40,000 totalExercise: $6.23Exp: 2031-03-01→ Common Stock (40,000 underlying) - Award
Stock Option (right to buy)
2021-03-01+220,000→ 220,000 totalExercise: $6.23Exp: 2031-03-01→ Common Stock (220,000 underlying) - Award
Stock Option (right to buy)
2021-03-01+40,000→ 40,000 totalExercise: $6.23Exp: 2031-03-01→ Common Stock (40,000 underlying)
Footnotes (4)
- [F1]The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
- [F2]The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020.
- [F3]The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021.
- [F4]The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021.
Documents
Issuer
Clovis Oncology, Inc.
CIK 0001466301
Entity typeother
Related Parties
1- filerCIK 0001266569
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 6:39 PM ET
- Size
- 12.6 KB